https://www.pharmaradar360.com/article/promising-biotech-stocks-to-follow-today-september-14th-ef83ca4efd667b1bPharmaRadar360en2026-09-14T16:04:48.000ZPromising Biotech Stocks To Follow Today - September 14thhttps://www.pharmaradar360.com/article/a-path-to-stability-at-fda-188b02c94a11daadPharmaRadar360en2026-09-14T15:56:05.000ZA Path to Stability at FDA?https://www.pharmaradar360.com/article/extracting-cbd-from-artisanal-practice-to-industrial-production-ccc31add2fafeeebPharmaRadar360en2026-09-14T15:51:14.000ZExtracting CBD: from artisanal practice to industrial productionhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-reports-earnings-results-for-the-half-year-ended-j-da34acb47d55b873PharmaRadar360en2026-09-14T15:50:27.000ZRTW Biotech Opportunities Ltd Reports Earnings Results for the Half Year Ended June 30, 2026https://www.pharmaradar360.com/article/pds-biotech-announces-initial-closing-of-up-to-22-3-mln-pipe-financing-b6b99a80672f80c4PharmaRadar360en2026-09-14T15:37:09.000ZPDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financinghttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-cheap-on-its-cantor-conference-spotlight-0c18fece4209bc40PharmaRadar360en2026-09-14T15:34:25.000ZIs Krystal Biotech (KRYS) Cheap On Its Cantor Conference Spotlight?https://www.pharmaradar360.com/article/fda-places-partial-clinical-hold-on-biohaven-s-epilepsy-drug-days-after-795-mill-fb310141e51e479dPharmaRadar360en2026-09-14T15:29:22.000ZFDA places partial clinical hold on Biohaven's epilepsy drug days after $795 million SK Biopharmaceuticals dealhttps://www.pharmaradar360.com/article/no-more-nordisk-novo-s-latest-trim-is-in-its-name-ac18f90a0e95918dPharmaRadar360en2026-09-14T15:22:30.000ZNo more Nordisk: Novo’s latest trim is in its namehttps://www.pharmaradar360.com/article/cover-of-vaccination-evaluated-rapidly-cover-programme-2026-to-2027-quarterly-da-854a7f00c802afc8PharmaRadar360en2026-09-14T15:13:36.000ZCover of vaccination evaluated rapidly (COVER) programme 2026 to 2027: quarterly datahttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharmaRadar360en2026-09-14T15:10:17.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/new-haven-biotech-seeks-to-raise-150m-for-drug-development-93d25e67402257aePharmaRadar360en2026-09-14T15:07:43.000ZNew Haven biotech seeks to raise $150M for drug developmenthttps://www.pharmaradar360.com/article/midcap-biotech-outlook-cmps-leads-on-trend-momentum-and-catalyst-timing-9644863c7fee914bPharmaRadar360en2026-09-14T15:02:42.000ZMidcap biotech outlook: CMPS leads on trend, momentum, and catalyst timinghttps://www.pharmaradar360.com/article/2025-2025-bb92cb39bafb6027PharmaRadar360en2026-09-14T15:00:00.000Z企業活動と医療機関等および患者団体の関係における透明性に関する指針等に基づき、「2025年度 医療機関等への資金提供等の実績」、「2025年度 患者団体への資金提供等の実績」を公開しましたhttps://www.pharmaradar360.com/article/dengue-the-green-book-chapter-d659d5bcdd75ad40PharmaRadar360en2026-09-14T14:52:11.000ZDengue: the green book chapterhttps://www.pharmaradar360.com/article/us-fda-grants-priority-review-to-zasocitinib-for-moderate-to-severe-pso-1e9daa76b6caf233PharmaRadar360en2026-09-14T14:50:59.000ZUS FDA Grants Priority Review to Zasocitinib for Moderate to Severe PsOhttps://www.pharmaradar360.com/article/pds-biotech-announces-initial-closing-of-up-to-22-3-million-pipe-financing-and-t-ca8e381455767ccdPharmaRadar360en2026-09-14T14:43:10.000ZPDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directorshttps://www.pharmaradar360.com/article/pds-biotechnology-raises-11-3-million-in-initial-closing-of-pipe-led-by-nant-cap-920b0390e9a9b55dPharmaRadar360en2026-09-14T14:40:00.000ZPDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Boardhttps://www.pharmaradar360.com/article/uk-covid-19-inquiry-53a03ab2ca904c16PharmaRadar360en2026-09-14T14:36:59.000ZUK Covid-19 Inquiryhttps://www.pharmaradar360.com/article/uk-government-response-to-the-covid-19-inquiry-module-3-report-82255ac20476e0dcPharmaRadar360en2026-09-14T14:36:34.000ZUK government response to the Covid-19 Inquiry Module 3 reporthttps://www.pharmaradar360.com/article/a-cancer-biotech-raises-11-3-million-the-los-angeles-times-owner-joins-its-board-36c5c0123605f906PharmaRadar360en2026-09-14T14:30:00.000ZA cancer biotech raises $11.3 million. The Los Angeles Times owner joins its board.https://www.pharmaradar360.com/article/definium-therapeutics-dftx-stock-soars-20-on-successful-phase-3-anxiety-trial-re-b93947691e55d7f8PharmaRadar360en2026-09-14T14:23:30.000ZDefinium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Resultshttps://www.pharmaradar360.com/article/nifst-stakeholders-seek-evidence-based-regulation-of-low-calorie-sweeteners-85989083eb27fcb7PharmaRadar360en2026-09-14T14:12:18.000ZNIFST, stakeholders seek evidence-based regulation of low-calorie sweetenershttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-appoints-robert-plenge-to-board-of-directors-b4f7261b09af2577PharmaRadar360en2026-09-14T14:09:12.000ZBioMarin Pharmaceutical appoints Robert Plenge to board of directorshttps://www.pharmaradar360.com/article/immunocore-achieves-full-enrollment-in-phase-3-tebe-am-melanoma-study-16e530c8f0b3f5f0PharmaRadar360en2026-09-14T14:02:17.000ZImmunocore Achieves Full Enrollment in Phase 3 TEBE-AM Melanoma Studyhttps://www.pharmaradar360.com/article/rezilient3-trial-efficacy-and-safety-data-of-zipalertinib-in-egfr-exon-20-insert-781f2e368253f241PharmaRadar360en2026-09-14T14:01:50.000ZREZILIENT3 Trial: Efficacy and Safety Data of Zipalertinib in EGFR Exon 20 Insertion NSCLChttps://www.pharmaradar360.com/article/recce-pharmaceuticals-asx-rce-phase-3-diabetic-foot-infection-trial-and-mena-lic-38124a0b87aac230PharmaRadar360en2026-09-14T13:58:00.000ZRecce Pharmaceuticals (ASX:RCE): Phase 3 Diabetic Foot Infection Trial and MENA Licensing Updatehttps://www.pharmaradar360.com/article/positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-e256990a7d983a8bPharmaRadar360en2026-09-14T13:54:36.000ZPositive Topline Results From Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorderhttps://www.pharmaradar360.com/article/veraxa-biotech-vrxa-insider-trading-activity-2026-249623a1453a3bf2PharmaRadar360en2026-09-14T13:48:00.000ZVeraxa Biotech (VRXA) Insider Trading Activity 2026https://www.pharmaradar360.com/article/gsk-touts-lung-cancer-data-from-two-drugs-8d677a7a22389a58PharmaRadar360en2026-09-14T13:38:49.000ZGSK touts lung cancer data from two drugshttps://www.pharmaradar360.com/article/biotech-growth-trust-extends-strong-performance-in-2026-d9b4635f68450caaPharmaRadar360en2026-09-14T13:32:34.000ZBiotech Growth Trust Extends Strong Performance In 2026https://www.pharmaradar360.com/article/sahpra-and-lesotho-strengthen-regional-collaboration-for-regulatory-excellence-45f1f401fec36a52PharmaRadar360en2026-09-14T13:23:20.000ZSAHPRA and Lesotho strengthen regional collaboration for regulatory excellencehttps://www.pharmaradar360.com/article/west-pharmaceutical-services-at-morgan-stanley-conference-growth-broadens-fe0c6b0b57907f44PharmaRadar360en2026-09-14T13:19:00.000ZWest Pharmaceutical Services at Morgan Stanley conference: growth broadenshttps://www.pharmaradar360.com/article/exclusive-dr-michael-c-burgess-we-need-a-new-playbook-to-guard-against-counterfe-6956c7305798f01dPharmaRadar360en2026-09-14T13:09:44.000ZExclusive—Dr. Michael C. Burgess: We Need a New Playbook to Guard Against Counterfeit Drug Ingredients from Chinahttps://www.pharmaradar360.com/article/sex-ratios-at-birth-in-the-uk-2019-to-2023-800293e4e71f3202PharmaRadar360en2026-09-14T13:05:00.000ZSex ratios at birth in the UK: 2019 to 2023https://www.pharmaradar360.com/article/biomarin-pharmaceutical-inc-nasdaq-bmrn-appoints-bms-r-d-chief-robert-plenge-to-d11aa567c7551aa2PharmaRadar360en2026-09-14T13:05:00.000ZBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Boardhttps://www.pharmaradar360.com/article/rabies-post-exposure-risk-assessment-d5bf37390bb160f1PharmaRadar360en2026-09-14T13:00:02.000ZRabies post exposure risk assessmenthttps://www.pharmaradar360.com/article/krtl-biotech-appoints-federal-controlled-substance-compliance-specialist-justin-4350832aa88145f3PharmaRadar360en2026-09-14T13:00:00.000ZKRTL Biotech Appoints Federal Controlled-Substance Compliance Specialist Justin Abril as President-Designatehttps://www.pharmaradar360.com/article/dare-bioscience-announces-peer-reviewed-publication-of-phase-1-sildenafil-cream-05d0eae494a7f684PharmaRadar360en2026-09-14T12:59:26.000ZDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafilhttps://www.pharmaradar360.com/article/organon-announces-us-fda-has-accepted-for-review-a-supplemental-new-drug-applica-6c0c0422506d902fPharmaRadar360en2026-09-14T12:57:01.000ZOrganon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Devicehttps://www.pharmaradar360.com/article/electra-aims-for-342m-ipo-to-power-inflammatory-drug-s-push-through-phase-3-0240e717903fd159PharmaRadar360en2026-09-14T12:52:57.000ZElectra aims for $342M IPO to power inflammatory drug’s push through phase 3https://www.pharmaradar360.com/article/5-small-drug-stocks-poised-to-benefit-from-a-biotech-recovery-570bf916e68b800aPharmaRadar360en2026-09-14T12:51:01.000Z5 Small Drug Stocks Poised to Benefit From a Biotech Recoveryhttps://www.pharmaradar360.com/article/j-j-looking-to-offload-orthopedics-unit-in-20b-deal-to-apollo-bloomberg-dc98416c34c5142aPharmaRadar360en2026-09-14T12:40:00.000ZJ&J looking to offload orthopedics unit in $20B deal to Apollo: Bloomberghttps://www.pharmaradar360.com/article/gatc-health-joins-critical-path-institute-s-new-approach-methodologies-developer-05166a46c1038966PharmaRadar360en2026-09-14T12:38:47.000ZGATC Health Joins Critical Path Institute’s New Approach Methodologies Developer Coalition to Advance AI-Enabled Regulatory Sciencehttps://www.pharmaradar360.com/article/cardiff-oncology-and-nerviano-medical-sciences-amend-their-2017-exclusive-licens-5715a4c53623c959PharmaRadar360en2026-09-14T12:38:44.000ZCardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreementhttps://www.pharmaradar360.com/article/the-biotech-growth-trust-plc-monthly-fact-sheet-as-at-31-august-2026-a063b8d62d709d23PharmaRadar360en2026-09-14T12:38:08.000ZThe Biotech Growth Trust PLC - Monthly Fact Sheet as at 31 August 2026https://www.pharmaradar360.com/article/etra-ipo-news-antibody-biotech-electra-therapeutics-sets-terms-for-325-million-i-0ecc46d14794d0abPharmaRadar360en2026-09-14T12:37:00.000ZETRA IPO News - Antibody biotech Electra Therapeutics sets terms for $325 million IPOhttps://www.pharmaradar360.com/article/geovax-and-cepi-enter-agreement-to-utilize-cepi-centralised-laboratory-network-t-68dec5d4551f2cf9PharmaRadar360en2026-09-14T12:37:00.000ZGeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trialhttps://www.pharmaradar360.com/article/global-cancer-drug-rights-dispute-settled-by-cardiff-and-nerviano-21e0f50be19d2e22PharmaRadar360en2026-09-14T12:30:00.000ZGlobal cancer drug rights dispute settled by Cardiff and Nervianohttps://www.pharmaradar360.com/article/acto-named-among-everest-group-s-top-50tm-pharmaceutical-technology-providers-fo-cc8fcd1bfda5c382PharmaRadar360en2026-09-14T12:30:00.000ZACTO Named Among Everest Group's Top 50™ Pharmaceutical Technology Providers for 2026https://www.pharmaradar360.com/article/biontech-nasdaq-bntx-lung-cancer-drug-extends-survival-vs-chemo-in-phase-3-c6832e849c4d7d59PharmaRadar360en2026-09-14T12:29:11.000ZBioNTech (NASDAQ: BNTX) lung cancer drug extends survival vs chemo in Phase 3https://www.pharmaradar360.com/article/major-shift-in-biotech-manufacturing-canva-0f67a9758151f283PharmaRadar360en2026-09-14T12:28:08.000ZMajor Shift in Biotech Manufacturing Canvahttps://www.pharmaradar360.com/article/leios-therapeutics-announces-positive-end-of-phase-2-meeting-with-fda-for-10xb-1-573671facadcb78fPharmaRadar360en2026-09-14T12:17:30.000ZLeios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullnesshttps://www.pharmaradar360.com/article/cancer-and-autoimmune-trials-define-legend-biotech-legn-cell-therapy-pipeline-e925d7051366c5a6PharmaRadar360en2026-09-14T12:09:14.000ZCancer and autoimmune trials define Legend Biotech (LEGN) cell therapy pipelinehttps://www.pharmaradar360.com/article/briacell-bctx-phase-3-trial-safety-endorsement-highlights-market-s-cautious-outl-2ca36055c44df42aPharmaRadar360en2026-09-14T12:09:13.000ZBriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlookhttps://www.pharmaradar360.com/article/data-safety-monitoring-board-recommends-continuing-briacell-s-phase-3-metastatic-00b5e7c605eb755fPharmaRadar360en2026-09-14T12:01:27.000ZData Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Studyhttps://www.pharmaradar360.com/article/a-48-hour-home-treatment-for-postpartum-depression-enters-a-new-study-about-120-6e444e94543dfa0aPharmaRadar360en2026-09-14T12:00:00.000ZA 48-hour home treatment for postpartum depression enters a new study. About 120 participants are planned.https://www.pharmaradar360.com/article/sls-stock-slumps-as-legal-scrutiny-hits-phase-3-trial-1f83efc08a3e0313PharmaRadar360en2026-09-14T11:47:00.000ZSLS Stock Slumps As Legal Scrutiny Hits Phase 3 Trialhttps://www.pharmaradar360.com/article/maharashtra-food-and-drug-administration-seizes-unsafe-dairy-products-e5136b5fcb9275cdPharmaRadar360en2026-09-14T11:43:22.000ZMaharashtra Food and Drug Administration seizes unsafe dairy productshttps://www.pharmaradar360.com/article/etf-movement-china-asset-management-hang-seng-biotech-etf-03069-surges-over-4-am-2b7d5a6e5fdce085PharmaRadar360en2026-09-14T11:34:43.000ZETF Movement | China Asset Management Hang Seng Biotech ETF (03069) Surges Over 4% Amid Frequent WCLC Clinical Data Releases; Institutions Bullish on Innovative Drug Investment Opportunitieshttps://www.pharmaradar360.com/article/medtronic-launches-exchange-offer-to-complete-separation-of-minimed-group-inc-e382312e420e5aaaPharmaRadar360en2026-09-14T11:30:00.000ZMedtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.https://www.pharmaradar360.com/article/a-breast-cancer-trial-gets-a-seventh-recommendation-to-continue-5b0431d8e7492c3cPharmaRadar360en2026-09-14T11:30:00.000ZA breast cancer trial gets a seventh recommendation to continuehttps://www.pharmaradar360.com/article/field-safety-notices-7-september-to-11-september-2026-593a20d84f2235c2PharmaRadar360en2026-09-14T11:25:18.000ZField Safety Notices: 7 September to 11 September 2026https://www.pharmaradar360.com/article/biomarin-pharmaceutical-nasdaq-bmrn-forms-tight-breakout-setup-with-strong-techn-8e3a96b30e8b630ePharmaRadar360en2026-09-14T11:20:40.000ZBioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicalshttps://www.pharmaradar360.com/article/pharmazz-inc-receives-u-s-fda-orphan-drug-designation-for-sovateltide-for-the-tr-a207e4ccbfb768c7PharmaRadar360en2026-09-14T11:15:23.000ZPharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)https://www.pharmaradar360.com/article/immunocore-announces-target-enrollment-achieved-in-phase-3-tebe-am-trial-of-kimm-23a53a59beab5bbePharmaRadar360en2026-09-14T11:12:00.000ZImmunocore Announces Target Enrollment Achieved in Phase 3 TEBE-AM Trial of KIMMTRAK in Previously Treated Advanced Melanomahttps://www.pharmaradar360.com/article/an-anxiety-treatment-met-every-key-goal-in-a-late-stage-trial-an-fda-meeting-is-0e9b1cfebc675f16PharmaRadar360en2026-09-14T11:02:53.000ZAn anxiety treatment met every key goal in a late-stage trial. An FDA meeting is planned for late 2026.https://www.pharmaradar360.com/article/nmn-2026-9-14-ceda7cee25400dc0PharmaRadar360en2026-09-14T11:00:00.000Z未来の自分を支える健康習慣へ ニコチンアミドモノヌクレオチドと長命草を配合したサプリメント「NMN」を 2026年9月14日に新発売https://www.pharmaradar360.com/article/israeli-ag-biotech-company-plans-north-american-headquarters-in-indiana-4a390f206c0be123PharmaRadar360en2026-09-14T11:00:00.000ZIsraeli Ag-Biotech Company Plans North American Headquarters in Indianahttps://www.pharmaradar360.com/article/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-s-2905618d20aa212aPharmaRadar360en2026-09-14T11:00:00.000ZDefinium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorderhttps://www.pharmaradar360.com/article/west-pharmaceutical-stock-holds-near-highs-after-strong-quarterly-beat-and-fresh-a94b2b2446bb6792PharmaRadar360en2026-09-14T10:57:20.000ZWest Pharmaceutical stock holds near highs after strong quarterly beat and fresh guidancehttps://www.pharmaradar360.com/article/definium-lsd-drug-goes-3-for-3-with-another-pivotal-trial-win-fdd1cdfaac12bccaPharmaRadar360en2026-09-14T10:57:18.000ZDefinium LSD drug goes 3 for 3 with another pivotal trial winhttps://www.pharmaradar360.com/article/scholar-rock-s-muscle-targeting-sma-therapy-isemblyd-lands-fda-approval-0c43d37e656f57b8PharmaRadar360en2026-09-14T10:50:12.000ZScholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approvalhttps://www.pharmaradar360.com/article/best-income-stocks-to-buy-for-september-14th-8c2cf2061f8628dbPharmaRadar360en2026-09-14T10:44:43.000ZBest Income Stocks to Buy for September 14thhttps://www.pharmaradar360.com/article/stifel-cuts-olema-pharmaceuticals-price-target-on-trial-concerns-0d5c9b3f2acc7cacPharmaRadar360en2026-09-14T10:42:00.000ZStifel cuts Olema Pharmaceuticals price target on trial concernshttps://www.pharmaradar360.com/article/lonza-deepens-us-bet-with-commercial-plant-in-oregon-a29a78ec68bd0365PharmaRadar360en2026-09-14T10:40:41.000ZLonza deepens US bet with commercial plant in Oregonhttps://www.pharmaradar360.com/article/fda-approves-telix-s-brain-cancer-imaging-drug-pixclara-449ed5b34cc35511PharmaRadar360en2026-09-14T10:34:27.000ZFDA Approves Telix’s Brain Cancer Imaging Drug Pixclarahttps://www.pharmaradar360.com/article/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasociti-66c11273bfee998ePharmaRadar360en2026-09-14T10:31:50.000ZU.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectationshttps://www.pharmaradar360.com/article/alcon-warns-that-us-proposal-could-cause-companies-to-abandon-europe-53d56b7bd75bdab8PharmaRadar360en2026-09-14T10:31:32.000ZAlcon warns that US proposal could cause companies to abandon Europehttps://www.pharmaradar360.com/article/the-fda-s-proposed-drug-ad-rule-is-a-blueprint-for-violating-the-first-amendment-7fa4cc4a983c3d2fPharmaRadar360en2026-09-14T10:30:39.000ZThe FDA’s Proposed Drug Ad Rule Is a Blueprint for Violating the First Amendmenthttps://www.pharmaradar360.com/article/first-in-human-clinical-trial-attacks-pancreatic-cancer-with-laser-light-50201537c62719b8PharmaRadar360en2026-09-14T10:30:36.000ZFirst-in-Human Clinical Trial Attacks Pancreatic Cancer With Laser Lighthttps://www.pharmaradar360.com/article/fda-grants-priority-review-to-takeda-nyse-tak-pill-for-severe-psoriasis-d7295820babd3de5PharmaRadar360en2026-09-14T10:26:20.000ZFDA grants priority review to Takeda (NYSE: TAK) pill for severe psoriasishttps://www.pharmaradar360.com/article/merck-provides-keytruda-at-no-cost-for-a-cancer-trial-7d3d50d0d822e36ePharmaRadar360en2026-09-14T10:16:00.000ZMerck provides Keytruda at no cost for a cancer trialhttps://www.pharmaradar360.com/article/morocco-s-pharmaceutical-trade-deficit-to-reach-1-4-billion-by-2030-9d175f14f5356cfbPharmaRadar360en2026-09-14T10:10:55.000ZMorocco’s Pharmaceutical Trade Deficit to Reach $1.4 Billion by 2030https://www.pharmaradar360.com/article/speaker-fees-and-buy-and-bill-keep-doctors-loyal-to-pharma-0bcba66a606f3cfaPharmaRadar360en2026-09-14T10:09:13.000ZSpeaker Fees and Buy-and-Bill Keep Doctors Loyal to Pharmahttps://www.pharmaradar360.com/article/why-fragmented-contract-processes-are-slowing-pharmaceutical-operations-cd7413f3e757257dPharmaRadar360en2026-09-14T10:06:49.000ZWhy Fragmented Contract Processes Are Slowing Pharmaceutical Operationshttps://www.pharmaradar360.com/article/could-western-mass-be-to-food-s-future-what-boston-is-to-biotech-umass-is-bettin-6f37059da1382fafPharmaRadar360en2026-09-14T10:03:41.000ZCould Western Mass be to food’s future what Boston is to biotech? UMass is betting on it with $120 million.https://www.pharmaradar360.com/article/pharmaceutical-industry-corruption-is-structural-systemic-and-profitable-new-rev-b115c9249c53f64ePharmaRadar360en2026-09-14T10:00:06.000ZPharmaceutical Industry Corruption Is Structural, Systemic, and Profitable, New Review Findshttps://www.pharmaradar360.com/article/rtw-biotech-makes-16-5-half-year-return-as-surge-in-listed-drug-developers-outwe-edb7b30944ab4575PharmaRadar360en2026-09-14T09:54:09.000ZRTW Biotech makes 16.5% half-year return as surge in listed drug developers outweighs write-down of Ensomahttps://www.pharmaradar360.com/article/a-fourth-ukrainian-pharmaceutical-warehouse-has-burned-in-a-russian-strike-since-6eb47225c106b55aPharmaRadar360en2026-09-14T09:41:41.000ZA fourth Ukrainian pharmaceutical warehouse has burned in a Russian strike since the start of the monthhttps://www.pharmaradar360.com/article/what-supplement-formulators-can-borrow-from-pharmaceutical-delivery-science-f3579b8398254e3cPharmaRadar360en2026-09-14T09:39:35.000ZWhat supplement formulators can borrow from pharmaceutical delivery sciencehttps://www.pharmaradar360.com/article/pm-stresses-strengthening-egypt-s-pharmaceutical-industry-regulatory-system-8e45ce9f3a140f23PharmaRadar360en2026-09-14T09:33:13.000ZPM stresses strengthening Egypt’s pharmaceutical industry, regulatory systemhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-ltd-2026-q2-results-earnings-call-presentation-otcmkts-fcb651dd64e3d3c2PharmaRadar360en2026-09-14T09:31:37.000ZRTW Biotech Opportunities Ltd 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:RTWFF) 2026-09-14https://www.pharmaradar360.com/article/gotistobart-nearly-doubles-survival-in-pretreated-squamous-lung-cancer-838a3314261d298dPharmaRadar360en2026-09-14T09:29:21.000ZGotistobart nearly doubles survival in pretreated squamous lung cancerhttps://www.pharmaradar360.com/article/trump-s-drug-policy-may-raise-south-korea-prices-57fd68f8da342994PharmaRadar360en2026-09-14T09:24:47.000ZTrump's Drug Policy May Raise South Korea Priceshttps://www.pharmaradar360.com/article/ganpati-prasad-under-fda-watch-maharashtra-societies-told-to-follow-new-food-saf-630ea4175c9525b9PharmaRadar360en2026-09-14T09:21:37.000ZGanpati prasad under FDA watch: Maharashtra societies told to follow new food safety ruleshttps://www.pharmaradar360.com/article/scholar-rock-wins-fda-approval-for-isembyld-6fd7f56f5e278d83PharmaRadar360en2026-09-14T09:18:51.000ZScholar Rock wins FDA approval for Isembyldhttps://www.pharmaradar360.com/article/designing-the-exit-ip-strategy-for-venture-backed-biotech-patent-united-kingdom-90eb104909dcff8fPharmaRadar360en2026-09-14T09:13:04.000ZDesigning The Exit: IP Strategy For Venture-Backed Biotech - Patent - United Kingdomhttps://www.pharmaradar360.com/article/act-align-accelerate-europe-s-biotech-turning-point-aad0b26991fea488PharmaRadar360en2026-09-14T09:03:59.000ZAct, align, accelerate: Europe’s Biotech turning pointhttps://www.pharmaradar360.com/article/spain-pushes-eu-wide-market-access-toolbox-for-innovative-biotech-medicines-830f72c452b45ef1PharmaRadar360en2026-09-14T09:01:00.000ZSpain Pushes EU-Wide Market Access Toolbox for Innovative Biotech Medicineshttps://www.pharmaradar360.com/article/china-has-a-chokehold-on-your-medicine-cabinet-it-s-a-national-security-threat-b390c227c0199626PharmaRadar360en2026-09-14T09:00:01.000ZChina has a chokehold on your medicine cabinet. It’s a national security threathttps://www.pharmaradar360.com/article/hong-kong-stocks-rise-on-monday-on-tech-biotech-gains-trigiant-jumps-47-98c47dac2ec6c611PharmaRadar360en2026-09-14T08:45:38.000ZHong Kong Stocks Rise on Monday on Tech, Biotech Gains; Trigiant Jumps 47%https://www.pharmaradar360.com/article/a-prefix-is-no-shield-against-confusion-delhi-high-court-protects-biochem-eb4e0aa061fc398aPharmaRadar360en2026-09-14T08:31:34.000ZA Prefix Is No Shield Against Confusion: Delhi High Court Protects BIOCHEMhttps://www.pharmaradar360.com/article/biontech-says-lung-cancer-drug-candidate-prolonged-lives-in-trial-bb6ddfdd81a51991PharmaRadar360en2026-09-14T08:31:19.000ZBioNTech says lung cancer drug candidate prolonged lives in trialhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-august-2026-1b10eeb5524e0803PharmaRadar360en2026-09-14T08:31:11.000ZUK Clinical Research Delivery key performance indicators: data to August 2026https://www.pharmaradar360.com/article/biontech-says-lung-cancer-drug-candidate-prolonged-lives-in-trial-048c025d7109ee38PharmaRadar360en2026-09-14T08:30:37.000ZBioNTech says lung cancer drug candidate prolonged lives in trialhttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-september-2026-72c636c8940d0e12PharmaRadar360en2026-09-14T08:29:48.000ZUK Clinical Research Delivery key performance indicators: data to September 2026https://www.pharmaradar360.com/article/novo-will-adapt-to-the-changing-healthcare-market-with-a-new-visual-identity-f1df41c04eb14b89PharmaRadar360en2026-09-14T08:29:00.000ZNovo will adapt to the changing healthcare market with a new visual identityhttps://www.pharmaradar360.com/article/how-trump-s-pharmaceutical-plan-threatens-europe-higher-drug-prices-and-delays-i-50b78795a90ba91aPharmaRadar360en2026-09-14T08:20:57.000ZHow Trump’s pharmaceutical plan threatens Europe: Higher drug prices and delays in new therapieshttps://www.pharmaradar360.com/article/russia-strikes-fourth-ukrainian-pharmaceutical-warehouse-in-september-video-ed18c40308c28339PharmaRadar360en2026-09-14T08:16:14.000ZRussia strikes fourth Ukrainian pharmaceutical warehouse in September - VIDEOhttps://www.pharmaradar360.com/article/biontech-and-oncoc4-report-updated-phase-3-data-showing-gotistobart-nearly-doubl-32e2f4d485c7d29ePharmaRadar360en2026-09-14T08:10:00.000ZBioNTech and OncoC4 Report Updated Phase 3 Data Showing Gotistobart Nearly Doubles Overall Survival in Squamous NSCLChttps://www.pharmaradar360.com/article/taiho-pharmaceutical-co-ltd-taiho-oncology-inc-and-cullinan-therapeutics-inc-rep-f211a6db7e1ef0ddPharmaRadar360en2026-09-14T08:05:51.000ZTaiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/quarterly-epidemiological-commentary-mandatory-mrsa-mssa-and-gram-negative-bacte-476c46b5e267deccPharmaRadar360en2026-09-14T08:02:51.000ZQuarterly Epidemiological Commentary: mandatory MRSA, MSSA and Gram-negative bacteraemia and Clostridioides difficile infection, data up to April to June 2026https://www.pharmaradar360.com/article/biontech-s-gotistobart-a-breakthrough-in-lung-cancer-treatment-3d84066f3e6cd42aPharmaRadar360en2026-09-14T08:01:27.000ZBioNTech's Gotistobart: A Breakthrough in Lung Cancer Treatmenthttps://www.pharmaradar360.com/article/biontech-s-experimental-treatment-extended-survival-to-18-5-months-versus-10-0e0798bc527d2105PharmaRadar360en2026-09-14T08:00:00.000ZBioNTech’s experimental treatment extended survival to 18.5 months, versus 10https://www.pharmaradar360.com/article/vivian-l-borrero-rac-achieves-recognition-for-40-years-of-leadership-and-contrib-24dc3b41c574ff62PharmaRadar360en2026-09-14T07:57:36.000ZVivian L. Borrero, RAC, Achieves Recognition for 40 Years of Leadership and Contributions to Pharmaceutical and Medical Technologyhttps://www.pharmaradar360.com/article/amivantamab-plus-chemotherapy-achieves-34-3-month-os-in-egfr-exon-20-insertion-l-0da3afd250e51aebPharmaRadar360en2026-09-14T07:38:35.000ZAmivantamab plus chemotherapy achieves 34.3-month OS in EGFR exon 20 insertion lung cancerhttps://www.pharmaradar360.com/article/tam-peli-extends-survival-to-13-3-months-in-relapsed-small-cell-lung-cancer-353338a24f94a9c6PharmaRadar360en2026-09-14T07:38:35.000ZTam-Peli Extends Survival to 13.3 Months in Relapsed Small-Cell Lung Cancerhttps://www.pharmaradar360.com/article/mri-surveillance-alone-outperforms-mri-plus-radiation-in-sclc-trial-d1b659ade107b12aPharmaRadar360en2026-09-14T07:38:35.000ZMRI Surveillance Alone Outperforms MRI Plus Radiation in SCLC Trialhttps://www.pharmaradar360.com/article/emmaus-cedars-sinai-extend-pact-b072a5bba6875f3fPharmaRadar360en2026-09-14T07:38:22.000ZEmmaus, Cedars-Sinai Extend Pacthttps://www.pharmaradar360.com/article/challenges-facing-chinese-biotech-deals-de6788d32d76210dPharmaRadar360en2026-09-14T07:37:54.000ZChallenges Facing Chinese Biotech Dealshttps://www.pharmaradar360.com/article/south-korean-pharmaceutical-company-plans-to-produce-medicines-in-kazakhstan-2b892242f692f4bdPharmaRadar360en2026-09-14T07:36:40.000ZSouth Korean pharmaceutical company plans to produce medicines in Kazakhstanhttps://www.pharmaradar360.com/article/kazakhstan-and-south-korea-agree-on-joint-pharmaceutical-production-7d2e8b6386b25bcfPharmaRadar360en2026-09-14T07:36:00.000ZKazakhstan and South Korea agree on joint pharmaceutical productionhttps://www.pharmaradar360.com/article/takeda-s-zasocitinib-wins-fda-priority-review-in-bid-to-redefine-oral-psoriasis-3f04a01589462c27PharmaRadar360en2026-09-14T07:34:03.000ZTakeda’s Zasocitinib Wins FDA Priority Review in Bid to Redefine Oral Psoriasis Carehttps://www.pharmaradar360.com/article/kazakhstan-and-south-korea-agree-on-joint-pharmaceutical-production-fed78451972c2e24PharmaRadar360en2026-09-14T07:30:59.000ZKazakhstan and South Korea agree on joint pharmaceutical productionhttps://www.pharmaradar360.com/article/spotlight-on-innovative-pharmaceutical-companies-after-drug-pricing-reform-alteo-9d24cab8a2d849dePharmaRadar360en2026-09-14T07:20:27.000ZSpotlight on ‘Innovative Pharmaceutical Companies’ After Drug Pricing Reform... Alteogen and ABL Among Certified Firmshttps://www.pharmaradar360.com/article/fda-approves-new-brain-cancer-imaging-agent-from-telix-dfce838ed16dbfa7PharmaRadar360en2026-09-14T07:07:29.000ZFDA approves new brain cancer imaging agent from Telixhttps://www.pharmaradar360.com/article/90-ad4b01e1c266920aPharmaRadar360en2026-09-14T07:04:02.000ZΣυμμετοχή του ΕΟΦ στην 90η ΔΕΘ.https://www.pharmaradar360.com/article/u-s-fda-accepts-new-drug-application-under-priority-review-for-takeda-s-zasociti-ef17f61352cd7eaaPharmaRadar360en2026-09-14T07:00:00.000ZU.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectationshttps://www.pharmaradar360.com/article/statement-on-pabs-instrument-at-the-eighth-meeting-of-the-intergovernmental-work-46d8f7c7cf3e1461PharmaRadar360en2026-09-14T06:58:22.000ZStatement on PABS Instrument at the eighth meeting of the Intergovernmental Working Group (IGWG 8) on the WHO Pandemic Agreementhttps://www.pharmaradar360.com/article/trump-s-drug-plan-could-prompt-companies-to-raise-prices-outside-the-us-86468b2325ec3197PharmaRadar360en2026-09-14T06:52:21.000ZTrump's drug plan could prompt companies to raise prices outside the UShttps://www.pharmaradar360.com/article/kenya-explores-merck-partnership-in-biotechnology-and-local-pharmaceutical-manuf-4e4830bb94d8ddf5PharmaRadar360en2026-09-14T06:51:39.000ZKenya Explores Merck Partnership in Biotechnology and Local Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/nouveau-guide-destine-aux-promoteurs-pour-la-procedure-synchronisee-des-etudes-c-bf1ed68763a3326dPharmaRadar360en2026-09-14T06:48:58.000ZNouveau guide destiné aux promoteurs pour la procédure synchronisée des études combinées CTR–MDR/IVDRhttps://www.pharmaradar360.com/article/trastuzumab-botidotin-shows-11-1-month-pfs-vs-t-dm1-in-phase-3-trial-564267db7516eeaaPharmaRadar360en2026-09-14T06:43:35.000ZTrastuzumab Botidotin Shows 11.1-Month PFS vs T-DM1 in Phase 3 Trialhttps://www.pharmaradar360.com/article/three-biotech-catalysts-to-watch-this-fall-rare-rapp-and-pcvx-nasdaq-rare-b87c087230a5836ePharmaRadar360en2026-09-14T06:37:37.000ZThree Biotech Catalysts To Watch This Fall: RARE, RAPP And PCVX (NASDAQ:RARE)https://www.pharmaradar360.com/article/santen-pharmaceutical-new-drug-application-filing-accepted-for-review-in-china-f-5a0a1f604c868dd6PharmaRadar360en2026-09-14T06:37:11.000ZSanten Pharmaceutical : New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopiahttps://www.pharmaradar360.com/article/fourth-russian-attack-on-pharmaceutical-warehouse-this-month-facility-on-fire-in-fe9e711ab6f60d1dPharmaRadar360en2026-09-14T06:34:00.000ZFourth Russian attack on pharmaceutical warehouse this month: facility on fire in Odesahttps://www.pharmaradar360.com/article/huons-teams-up-with-three-biotech-startups-for-joint-new-drug-development-expand-79cfd35f6eadf712PharmaRadar360en2026-09-14T06:33:25.000ZHuons Teams Up with Three Biotech Startups for Joint New Drug Development... "Expanding External Research Model"https://www.pharmaradar360.com/article/ad0e5b477a2967caPharmaRadar360en2026-09-14T06:30:00.000Z人事のお知らせhttps://www.pharmaradar360.com/article/personnel-changes-7dcc223d059f37efPharmaRadar360en2026-09-14T06:30:00.000ZPersonnel Changeshttps://www.pharmaradar360.com/article/guide-destine-aux-promoteurs-pour-la-procedure-synchronisee-des-etudes-combinees-d566a9c40a897724PharmaRadar360en2026-09-14T06:22:55.000ZGuide destiné aux promoteurs pour la procédure synchronisée des études combinées CTR–MDR/IVDRhttps://www.pharmaradar360.com/article/9lione-a-pharmaceutical-distribution-dx-company-raises-120-million-in-series-a-l-977358ce07543d12PharmaRadar360en2026-09-14T06:19:54.000Z9lione, a Pharmaceutical Distribution DX Company, Raises ¥120 Million in Series A Led by Yokohama Capitalhttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-reports-august-nav-of-2-92-per-share-by-investing-com-f389326bb2eef80aPharmaRadar360en2026-09-14T06:10:25.000ZRTW Biotech Opportunities reports August NAV of $2.92 per share By Investing.comhttps://www.pharmaradar360.com/article/avacta-appoints-mats-blom-to-the-board-of-directors-as-chair-of-audit-committee-9cdbf75a711b7e6cPharmaRadar360en2026-09-14T06:01:42.000ZAvacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committeehttps://www.pharmaradar360.com/article/reg-rtw-biotech-opp-monthly-valuation-update-and-factsheet-2f129452d79a9f29PharmaRadar360en2026-09-14T06:01:00.000ZREG - RTW Biotech Opp. - Monthly Valuation Update and Factsheethttps://www.pharmaradar360.com/article/yuhan-corporation-unveils-clinical-trial-design-for-oral-her2-cancer-drug-yh4294-e92301864336810fPharmaRadar360en2026-09-14T05:55:00.000ZYuhan Corporation Unveils Clinical Trial Design for Oral HER2 Cancer Drug YH42946; Phase 2 Set for Early Next Yearhttps://www.pharmaradar360.com/article/fda-delays-review-of-exelixis-zanzalintinib-by-3-months-no-new-safety-issues-fou-406d52a642bf2331PharmaRadar360en2026-09-14T05:44:07.000ZFDA delays review of Exelixis' zanzalintinib by 3 months, no new safety issues foundhttps://www.pharmaradar360.com/article/daewon-pharmaceutical-hosts-vietnamese-delegation-at-smart-factory-c66774a452dccbe7PharmaRadar360en2026-09-14T05:37:43.000ZDaewon Pharmaceutical Hosts Vietnamese Delegation at Smart Factoryhttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-cmg-pharmaceutical-co-ltd-krx-058820-402e367de1aa6bfcPharmaRadar360en2026-09-14T05:20:20.000ZPrice to earnings forward of CMG Pharmaceutical Co., Ltd. – KRX:058820https://www.pharmaradar360.com/article/fda-approves-viiv-s-tivicay-pd-for-newborn-hiv-patients-bc39eeceea971edbPharmaRadar360en2026-09-14T05:16:30.000ZFDA Approves ViiV’s Tivicay PD for Newborn HIV Patientshttps://www.pharmaradar360.com/article/allan-shaw-biotech-s-real-risk-isn-t-dilution-it-s-building-a-brand-of-generic-b90057b607ebcb91PharmaRadar360en2026-09-14T05:08:00.000ZAllan Shaw: Biotech's Real Risk Isn't Dilution — It's Building a 'Brand of Generic'https://www.pharmaradar360.com/article/noxopharm-moves-lupus-skin-therapy-toward-next-human-trial-4c0656af8b7f5c97PharmaRadar360en2026-09-14T05:04:02.000ZNoxopharm moves lupus skin therapy toward next human trialhttps://www.pharmaradar360.com/article/4-best-gene-editing-stocks-for-2026-and-how-to-invest-2370cdd322149d26PharmaRadar360en2026-09-14T04:31:00.000Z4 Best Gene-Editing Stocks for 2026 and How to Investhttps://www.pharmaradar360.com/article/rebuilding-food-safety-regulation-in-the-united-states-c37766891763882dPharmaRadar360en2026-09-14T04:23:46.000ZRebuilding Food Safety Regulation in the United Stateshttps://www.pharmaradar360.com/article/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-mean-de95279f4726a52bPharmaRadar360en2026-09-14T03:57:18.000ZIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in Chinahttps://www.pharmaradar360.com/article/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-surv-9d2c4846e90ee934PharmaRadar360en2026-09-14T03:57:18.000ZZipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/astrazeneca-s-drug-delayed-lung-cancer-progression-by-6-months-in-a-trial-85662fec9375d10aPharmaRadar360en2026-09-14T03:56:15.000ZAstraZeneca's drug delayed lung cancer progression by 6 months in a trialhttps://www.pharmaradar360.com/article/china-warns-us-over-alleged-espionage-targeting-ai-chip-biotech-companies-bf9f9adcacb5b3daPharmaRadar360en2026-09-14T03:36:00.000ZChina warns US over alleged espionage targeting AI, chip, biotech companieshttps://www.pharmaradar360.com/article/79-were-alive-eight-years-later-on-astrazeneca-s-lung-cancer-drug-versus-64-on-p-98fd92d7250b9744PharmaRadar360en2026-09-14T02:18:14.000Z79% were alive eight years later on AstraZeneca's lung-cancer drug, versus 64% on placebo.https://www.pharmaradar360.com/article/phase-3-destiny-lung04-trial-shows-first-line-trastuzumab-deruxtecan-significant-547549369a0f3eabPharmaRadar360en2026-09-14T02:13:20.000ZPhase 3 DESTINY-Lung04 trial shows first-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant NSCLChttps://www.pharmaradar360.com/article/cullinan-taiho-showcase-6-month-survival-benefit-in-phase-3-trial-for-advanced-l-ac746721ed14d229PharmaRadar360en2026-09-14T01:44:33.000ZCullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerhttps://www.pharmaradar360.com/article/ai-driven-pharmaceutical-r-d-infrastructure-competition-key-trends-strategies-in-a02a6e13d45ee46dPharmaRadar360en2026-09-14T01:11:43.000ZAI-Driven Pharmaceutical R&D Infrastructure Competition: Key Trends, Strategies & Industry Impacthttps://www.pharmaradar360.com/article/the-eastward-shift-in-the-biotech-world-why-india-and-china-could-lead-the-next-c7351acce8a9a57ePharmaRadar360en2026-09-14T01:00:00.000ZThe eastward shift in the biotech world: Why India and China could lead the next wavehttps://www.pharmaradar360.com/article/zipalertinib-plus-chemotherapy-demonstrates-6-month-median-progression-free-surv-d8ea6923c50c50bePharmaRadar360en2026-09-14T00:00:00.000ZZipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-8f0a4cbe341f351bPharmaRadar360en2026-09-14T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/biontech-filed-form-6-k-47a909258d7896e0PharmaRadar360en2026-09-14T00:00:00.000ZBioNTech filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-e03dfe4679ebf435PharmaRadar360en2026-09-14T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/santen-new-drug-application-filing-accepted-for-review-in-china-for-stn1012700-a-f5d677282047d1cfPharmaRadar360en2026-09-14T00:00:00.000ZSanten New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopiahttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-43af7f508aad5808PharmaRadar360en2026-09-14T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-0a2f52c48bbe338fPharmaRadar360en2026-09-14T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-22092c86d7df9466PharmaRadar360en2026-09-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-2d158a641081c0cdPharmaRadar360en2026-09-14T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-d076b55218c8a2fbPharmaRadar360en2026-09-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-2e7d222acc44a9c2PharmaRadar360en2026-09-14T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-dbbe71b996495e15PharmaRadar360en2026-09-14T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a565d16132d7098aPharmaRadar360en2026-09-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-41789f04c6bc98f9PharmaRadar360en2026-09-14T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e8036bd141f5d31dPharmaRadar360en2026-09-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-50744185ac6a0574PharmaRadar360en2026-09-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-368730ee7afce07fPharmaRadar360en2026-09-14T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-3eebdf6c19a690f3PharmaRadar360en2026-09-14T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-4ff70bffc7142a1dPharmaRadar360en2026-09-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/importer-of-controlled-substances-application-irvine-labs-inc-1350cffdd1f6ab38PharmaRadar360en2026-09-14T00:00:00.000ZImporter of Controlled Substances Application: Irvine Labs, Inc.https://www.pharmaradar360.com/article/bulk-manufacturer-of-controlled-substances-application-cambrex-high-point-inc-008e3b2bc6e1d789PharmaRadar360en2026-09-14T00:00:00.000ZBulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.https://www.pharmaradar360.com/article/agency-forms-undergoing-paperwork-reduction-act-review-dce179460387c8aePharmaRadar360en2026-09-14T00:00:00.000ZAgency Forms Undergoing Paperwork Reduction Act Reviewhttps://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-for-expanding-outreach-f9898d8cf2a86252PharmaRadar360en2026-09-14T00:00:00.000ZAnnouncing the Intent To Award a Single-Source Supplement for Expanding Outreach and Professional Training To Engage Older Adults With Behavioral Health Conditions in Evidence-Based Health Promotion Programshttps://www.pharmaradar360.com/article/solicitation-for-nominations-to-serve-on-the-advisory-council-to-support-grandpa-6ebc6e265a932df5PharmaRadar360en2026-09-14T00:00:00.000ZSolicitation for Nominations To Serve on the Advisory Council To Support Grandparents Raising Grandchildrenhttps://www.pharmaradar360.com/article/solicitation-for-nominations-to-serve-on-the-family-caregiving-advisory-council-31910611e58db2c4PharmaRadar360en2026-09-14T00:00:00.000ZSolicitation for Nominations To Serve on the Family Caregiving Advisory Councilhttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-8f8b60381133a48aPharmaRadar360en2026-09-14T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Customer/Partner Customer Service Satisfaction Surveyshttps://www.pharmaradar360.com/article/office-of-the-national-coordinator-for-health-information-technology-health-info-b544a4acb9b8b8f6PharmaRadar360en2026-09-14T00:00:00.000ZOffice of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; Amended Notice of Meetinghttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-b02f31e37dc3ec91PharmaRadar360en2026-09-14T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/proposed-collection-60-day-comment-request-nih-electronic-application-system-for-1920dece3f62af8fPharmaRadar360en2026-09-14T00:00:00.000ZProposed Collection; 60-Day Comment Request; NIH Electronic Application System for NIH Certificates of Confidentiality (CoC)https://www.pharmaradar360.com/article/draft-nih-biosafety-policy-for-research-involving-biohazards-29b2690afa1577d6PharmaRadar360en2026-09-14T00:00:00.000ZDraft NIH Biosafety Policy for Research Involving Biohazardshttps://www.pharmaradar360.com/article/cleveland-clinic-begins-offering-appointment-only-flu-vaccinations-5c438e2467aed99fPharmaRadar360en2026-09-14T00:00:00.000ZCleveland Clinic Begins Offering Appointment-Only Flu Vaccinationshttps://www.pharmaradar360.com/article/smart-pharmaceutical-packaging-market-forecast-report-featuring-segment-analysis-55a8d6ef43850c1dPharmaRadar360en2026-09-14T00:00:00.000ZSmart Pharmaceutical Packaging Market Forecast Report Featuring Segment Analysis And Strategic Industry Insighthttps://www.pharmaradar360.com/article/implications-of-potential-us-fda-approval-of-psychedelics-or-psychedelic-adjacen-8b3f3520f48b0627PharmaRadar360en2026-09-14T00:00:00.000ZImplications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japanhttps://www.pharmaradar360.com/article/efficacy-and-safety-of-celecoxib-combined-with-jintiange-capsules-for-the-treatm-e71b3692cb8b1294PharmaRadar360en2026-09-14T00:00:00.000ZEfficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.https://www.pharmaradar360.com/article/lipoprotein-a-in-japan-an-expert-consensus-statement-9e5280d6ea38688cPharmaRadar360en2026-09-14T00:00:00.000ZLipoprotein(a) in Japan: An Expert Consensus Statement.https://www.pharmaradar360.com/article/encarcelando-eslabones-descartables-microtrafico-en-mujeres-bolivianas-y-su-vinc-78099e7bb631f301PharmaRadar360en2026-09-14T00:00:00.000ZEncarcelando eslabones descartables: microtráfico en mujeres bolivianas y su vinculación con comunidades indígenas y evangélicas intra y extracarcelariashttps://www.pharmaradar360.com/article/endoscopic-retrograde-cholangiopancreatography-versus-endoscopic-ultrasound-guid-06fe4129655d1ee6PharmaRadar360en2026-09-14T00:00:00.000ZEndoscopic retrograde cholangiopancreatography versus endoscopic ultrasound-guided primary biliary drainage for malignant distal biliary obstruction: a reviewhttps://www.pharmaradar360.com/article/comparison-of-outcome-of-sac-ligation-versus-no-sac-ligation-in-pediatric-patien-532a18f6cf6f4daaPharmaRadar360en2026-09-14T00:00:00.000ZCOMPARISON OF OUTCOME OF SAC LIGATION VERSUS NO SAC LIGATION IN PEDIATRIC PATIENTS UNDERGOING INGUINAL ORCHIDOPEXY FOR INCOMPLETELY DESCENDED PALPABLE TESTES: A RANDOMIZED CONTROLLED TRIALhttps://www.pharmaradar360.com/article/comparative-trial-of-periumbilical-incision-versus-intraumbilical-incision-in-em-3b7d7e84584d0075PharmaRadar360en2026-09-14T00:00:00.000ZCOMPARATIVE TRIAL OF PERIUMBILICAL INCISION VERSUS INTRAUMBILICAL INCISION IN EMERGENCY LAPAROSCOPIC APPENDECTOMY IN A HIGH VOLUME LAPAROSCOPIC SURGERY CENTREhttps://www.pharmaradar360.com/article/penicillin-a-journey-from-a-magic-bullet-to-a-resistant-drug-9f783258c6f90946PharmaRadar360en2026-09-14T00:00:00.000ZPENICILLIN: A JOURNEY FROM A MAGIC BULLET TO A RESISTANT DRUGhttps://www.pharmaradar360.com/article/inside-the-community-alongside-clinical-practice-community-music-therapy-as-soci-e648dcea05dfc2dcPharmaRadar360en2026-09-14T00:00:00.000ZInside the community, alongside clinical practice: Community music therapy as social infrastructurehttps://www.pharmaradar360.com/article/tuberculosis-resistente-a-farmacos-y-factores-asociados-en-santa-fe-2021-2024-c10ac6bde98c4961PharmaRadar360en2026-09-14T00:00:00.000ZTuberculosis resistente a fármacos y factores asociados en Santa Fe (2021-2024)https://www.pharmaradar360.com/article/in-silico-adme-toxicity-profiling-of-3-4-dithia-1-azabicyclo-3-2-0-heptan-7-one-caf23f7a863538aaPharmaRadar360en2026-09-14T00:00:00.000ZIn Silico ADME–Toxicity Profiling of 3,4-dithia-1-azabicyclo[3.2.0]heptan-7-one: Integrating Drug-Likeness, Pharmacokinetics, and Prediction Confidencehttps://www.pharmaradar360.com/article/genicular-artery-embolization-in-primary-and-secondary-knee-osteoarthritis-clini-9bb5724954bb9262PharmaRadar360en2026-09-14T00:00:00.000ZGenicular artery embolization in primary and secondary knee osteoarthritis: clinical success, patient-perceived satisfaction, and recurrencehttps://www.pharmaradar360.com/article/clinical-outcomes-of-tep-and-lichtenstein-repair-in-bilateral-inguinal-hernia-su-75f20d92150782daPharmaRadar360en2026-09-14T00:00:00.000ZClinical Outcomes of TEP and Lichtenstein Repair in Bilateral Inguinal Hernia Surgery: A Retrospective Comparative Studyhttps://www.pharmaradar360.com/article/clinical-significance-of-incidental-colorectal-fdg-avid-lesions-on-oncologic-18f-ed6e93d4e1e114bePharmaRadar360en2026-09-14T00:00:00.000ZClinical Significance of Incidental Colorectal FDG-Avid Lesions on Oncologic 18F-FDG PET/CT: Colonoscopy and Pathology Correlationhttps://www.pharmaradar360.com/article/the-effect-of-soft-tissue-mobilization-and-kinesio-taping-on-sportive-performanc-99d998bcb0793088PharmaRadar360en2026-09-14T00:00:00.000ZThe Effect of Soft Tissue Mobilization and Kinesio Taping on Sportive Performance in Athletes: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/unveiling-ai-augmented-periodontal-decision-making-a-comparative-clinical-evalua-afd3857e16b239ebPharmaRadar360en2026-09-14T00:00:00.000ZUnveiling AI-Augmented Periodontal Decision-Making: A Comparative Clinical Evaluation of Diagnocat-Based Radiographic Deep Learning and ChatGPT-Driven Treatment Planning Versus Clinical Expert Judgementhttps://www.pharmaradar360.com/article/utilization-of-long-acting-injectable-antipsychotics-and-clozapine-in-coordinate-b1a839103df3000dPharmaRadar360en2026-09-14T00:00:00.000ZUtilization of Long-Acting Injectable Antipsychotics and Clozapine in Coordinated Specialty Carehttps://www.pharmaradar360.com/article/clinical-translational-nephrology-in-global-primary-care-bridging-innovation-pre-7f9c25f39ef7100aPharmaRadar360en2026-09-14T00:00:00.000ZClinical translational nephrology in global primary care: bridging innovation, prevention, and equityhttps://www.pharmaradar360.com/article/diagnostic-performance-of-fine-needle-aspiration-i-vs-i-fine-needle-biopsy-in-so-dbf723366d924d81PharmaRadar360en2026-09-14T00:00:00.000ZDiagnostic performance of fine-needle aspiration <i>vs</i> fine-needle biopsy in solid pancreatic lesions based on pathologist expertise: A prospective multicenter trialhttps://www.pharmaradar360.com/article/rural-urban-differences-in-breast-cancer-epidemiology-nutritional-status-and-cli-bbc480129a89ee6aPharmaRadar360en2026-09-14T00:00:00.000ZRural-Urban Differences in Breast Cancer Epidemiology, Nutritional Status, and Clinical Presentation: A Comparative Multi-Center Study from Southern Rajasthanhttps://www.pharmaradar360.com/article/quasi-experimental-trial-examining-the-effectiveness-of-driver-training-modules-b9eb6d77db7b1dabPharmaRadar360en2026-09-14T00:00:00.000ZQuasi-Experimental Trial Examining the Effectiveness of Driver Training Modules on Simulated Driving Performance in Young Drivershttps://www.pharmaradar360.com/article/clinical-translation-of-fisetin-for-age-related-diseases-current-evidence-and-fu-3668d87d5ee7a0caPharmaRadar360en2026-09-14T00:00:00.000ZClinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunitieshttps://www.pharmaradar360.com/article/asthma-and-sinonasal-diseases-shared-clinical-comorbidities-inflammatory-pathway-afac4b7bf1e62340PharmaRadar360en2026-09-14T00:00:00.000ZAsthma and Sinonasal Diseases: Shared Clinical Comorbidities, Inflammatory Pathways and Management Strategieshttps://www.pharmaradar360.com/article/preoperative-frailty-inflammation-phenotypes-and-early-functional-and-patient-re-7f649c25063dbf2aPharmaRadar360en2026-09-14T00:00:00.000ZPreoperative Frailty-Inflammation Phenotypes and Early Functional and Patient-Reported Recovery After Head-and-Neck Oncologic Reconstruction: An Exploratory Prospective Single-Center Cohort Studyhttps://www.pharmaradar360.com/article/prenatal-and-postnatal-identification-of-phelan-mcdermid-syndrome-in-a-tertiary-1992aa669c4b0d5ePharmaRadar360en2026-09-14T00:00:00.000ZPrenatal and Postnatal Identification of Phelan–McDermid Syndrome in a Tertiary Referral Center: A 15-Case Series and Literature Reviewhttps://www.pharmaradar360.com/article/the-impact-of-differential-posterior-tibial-slope-on-clinical-outcomes-following-42a7ccaaa95fd46cPharmaRadar360en2026-09-14T00:00:00.000ZThe Impact of Differential Posterior Tibial Slope on Clinical Outcomes Following Revision ACL Surgery: A Retrospective Single-Centre Studyhttps://www.pharmaradar360.com/article/paired-urinary-cytology-and-targeted-fgfr3-s249c-r248c-mutation-detection-in-uri-4f195e94a047b77ePharmaRadar360en2026-09-14T00:00:00.000ZPaired Urinary Cytology and Targeted FGFR3 S249C/R248C Mutation Detection in Urine from Patients with Bladder Cancer: A Pilot Studyhttps://www.pharmaradar360.com/article/serum-granzyme-b-in-parkinson-s-disease-a-case-control-study-of-diagnostic-assoc-915548369384ad65PharmaRadar360en2026-09-14T00:00:00.000ZSerum Granzyme B in Parkinson’s Disease: A Case–Control Study of Diagnostic Associationhttps://www.pharmaradar360.com/article/clinical-outcomes-of-ankaferd-hemostat-mouthwash-for-high-grade-oral-mucositis-d-dd6bbd11a2889475PharmaRadar360en2026-09-14T00:00:00.000ZClinical Outcomes of Ankaferd Hemostat Mouthwash for High-Grade Oral Mucositis During Systemic Anticancer Therapy: A Single-Center, Retrospective, Single-Arm Cohort Studyhttps://www.pharmaradar360.com/article/responsible-clinical-ai-in-dentistry-trust-professional-autonomy-and-perceptions-bf5bf089fe84f1c4PharmaRadar360en2026-09-14T00:00:00.000ZResponsible Clinical AI in Dentistry: Trust, Professional Autonomy, and Perceptions of Accountability Across Stakeholders in Romania—A Multidisciplinary Cross-Sectional Surveyhttps://www.pharmaradar360.com/article/the-global-burden-of-eustachian-tube-dysfunction-in-older-patients-pathophysiolo-458aaa33a1cfbbdcPharmaRadar360en2026-09-14T00:00:00.000ZThe Global Burden of Eustachian Tube Dysfunction in Older Patients: Pathophysiology, Clinical Consequences, Diagnostic Challenges and Therapeutic Perspectives—A SANRA-Based Studyhttps://www.pharmaradar360.com/article/therapeutic-advances-in-spinal-muscular-atrophy-a-review-of-clinical-safety-and-d99e25370b464471PharmaRadar360en2026-09-14T00:00:00.000ZTherapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerationshttps://www.pharmaradar360.com/article/assessment-of-minimum-discard-volume-for-central-venous-catheter-sampling-valida-face44472c6caf57PharmaRadar360en2026-09-14T00:00:00.000ZAssessment of minimum discard volume for central venous catheter sampling: Validation via busulfan therapeutic drug monitoring in pediatric transplant patientshttps://www.pharmaradar360.com/article/artificial-intelligence-in-colorectal-cancer-multidisciplinary-decision-making-c-5b2c364273f7c68cPharmaRadar360en2026-09-14T00:00:00.000ZArtificial intelligence in colorectal cancer multidisciplinary decision-making: concordance, predictive support and clinical translationhttps://www.pharmaradar360.com/article/piwil4-from-biological-characteristics-to-disease-pathogenesis-and-clinical-appl-fe625d656dadd63fPharmaRadar360en2026-09-14T00:00:00.000ZPIWIL4: from biological characteristics to disease pathogenesis and clinical applicationshttps://www.pharmaradar360.com/article/secretory-carrier-membrane-protein-3-modulates-nuclear-erk1-2-signaling-and-drug-f0a176772406d686PharmaRadar360en2026-09-14T00:00:00.000ZSecretory carrier membrane protein 3 modulates nuclear ERK1/2 signaling and drug response in triple-negative breast cancerhttps://www.pharmaradar360.com/article/medicinal-mushrooms-and-type-2-diabetes-mechanistic-insights-translational-evide-c67fcbde1cdfbd95PharmaRadar360en2026-09-14T00:00:00.000ZMedicinal mushrooms and type 2 diabetes: mechanistic insights, translational evidence, and clinical caveatshttps://www.pharmaradar360.com/article/the-clinical-effects-of-probiotic-supplementations-on-metabolic-syndrome-a-syste-3ee1432f47c34b56PharmaRadar360en2026-09-14T00:00:00.000ZThe clinical effects of probiotic supplementations on metabolic syndrome: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/controlled-low-central-venous-pressure-after-cardiopulmonary-bypass-reduces-acut-377e84517695fe80PharmaRadar360en2026-09-14T00:00:00.000ZControlled low central venous pressure after cardiopulmonary bypass reduces acute kidney injury following cardiac surgery: a randomized controlled trialhttps://www.pharmaradar360.com/article/immune-microbe-interactions-in-pediatric-ulcerative-colitis-clinical-features-pa-a9a0449f50bfee25PharmaRadar360en2026-09-14T00:00:00.000ZImmune–microbe interactions in pediatric ulcerative colitis: clinical features, pathogenesis, and novel targeted therapeutic strategieshttps://www.pharmaradar360.com/article/immune-checkpoint-inhibitor-associated-arrhythmias-clinical-challenges-artificia-ae5d84fef5706750PharmaRadar360en2026-09-14T00:00:00.000ZImmune checkpoint inhibitor-associated arrhythmias: clinical challenges, artificial intelligence-enhanced monitoring, and management strategieshttps://www.pharmaradar360.com/article/porous-silicon-nanoparticles-in-drug-delivery-regenerative-medicine-and-biosensi-1227a29e48efd94ePharmaRadar360en2026-09-14T00:00:00.000ZPorous silicon nanoparticles in drug delivery, regenerative medicine, and biosensing: a translational reviewhttps://www.pharmaradar360.com/article/closed-loop-non-invasive-ventilation-in-critical-care-current-evidence-and-clini-2f6f8236ab093ddaPharmaRadar360en2026-09-14T00:00:00.000ZClosed-loop non-invasive ventilation in critical care: current evidence and clinical perspectiveshttps://www.pharmaradar360.com/article/unraveling-the-mystery-of-status-epilepticus-a-retrospective-study-at-a-tertiary-a9048ab8cd680ff1PharmaRadar360en2026-09-14T00:00:00.000ZUnraveling the mystery of status epilepticus: a retrospective study at a tertiary care centre from Indiahttps://www.pharmaradar360.com/article/evaluation-of-biofertigation-for-enhancing-growth-and-yield-of-blackgram-vigna-m-ac7b85d563f235a6PharmaRadar360en2026-09-14T00:00:00.000ZEvaluation of Biofertigation for Enhancing Growth and Yield of Blackgram (Vigna mungo L.)https://www.pharmaradar360.com/article/comparative-phytochemical-screening-and-in-vitro-anthelmintic-evaluation-of-etha-ce97e601cabab040PharmaRadar360en2026-09-14T00:00:00.000ZComparative Phytochemical Screening and In Vitro Anthelmintic Evaluation of Ethanolic and Petroleum Ether Leaf Extracts of Bougainvillea spectabilis Willd. Against Pheretima posthumahttps://www.pharmaradar360.com/article/modified-tibial-plateau-leveling-osteotomy-using-a-precontoured-plate-achieves-s-73e5b5184a8265e7PharmaRadar360en2026-09-14T00:00:00.000ZModified tibial plateau-leveling osteotomy using a precontoured plate achieves single-stage correction with favorable clinical outcomes in small-breed dogshttps://www.pharmaradar360.com/article/a-computational-study-of-some-cancer-causing-s100-proteins-interacting-with-a-li-03ed20d4c40a4d43PharmaRadar360en2026-09-14T00:00:00.000ZA Computational Study of Some Cancer Causing S100 Proteins Interacting With a Ligand, Parecoxib and Investigation of Drug Likenes Potential of the Ligandhttps://www.pharmaradar360.com/article/pharmaceutical-care-for-patients-with-leprosy-impact-on-treatment-adherence-and-008e2fd16c1d0c1cPharmaRadar360en2026-09-14T00:00:00.000ZPharmaceutical care for patients with leprosy: impact on treatment adherence and pharmacotherapy safetyhttps://www.pharmaradar360.com/article/development-and-external-validation-of-a-machine-learning-based-clinical-predict-4d88db5e80c48cbaPharmaRadar360en2026-09-14T00:00:00.000ZDevelopment and External Validation of a Machine Learning–Based Clinical Prediction Model for Postoperative Ischemic Stroke in Patients Undergoing Coronary Artery Bypass Grafting: Validation Using the eICU Collaborative Research Databasehttps://www.pharmaradar360.com/article/associations-of-pretreatment-neutrophil-to-lymphocyte-ratio-and-thyroid-related-dbbd59bacc22f2b8PharmaRadar360en2026-09-14T00:00:00.000ZAssociations of pretreatment neutrophil-to-lymphocyte ratio and thyroid-related immune-related adverse events with clinical outcomes in advanced upper gastrointestinal malignancies treated with immunotherapy: a retrospective cohort studyhttps://www.pharmaradar360.com/article/the-effect-of-reminiscence-therapy-on-the-resilience-and-satisfaction-with-care-d442db71ae84ac7cPharmaRadar360en2026-09-14T00:00:00.000ZThe Effect of Reminiscence Therapy on the Resilience and Satisfaction with Care in Mothers of Premature Infants Hospitalized in Neonatal Intensive Care Units: A Clinical Trial Studyhttps://www.pharmaradar360.com/article/beta-lactam-dose-optimization-using-therapeutic-drug-monitoring-in-pediatric-pat-e3ca0a48c61a6b6bPharmaRadar360en2026-09-14T00:00:00.000ZBeta-Lactam Dose Optimization Using Therapeutic Drug Monitoring in Pediatric Patientshttps://www.pharmaradar360.com/article/preparation-of-transdermal-patch-as-a-drug-delivery-system-for-treatment-of-urin-b682b2e2a273a1b5PharmaRadar360en2026-09-14T00:00:00.000ZPreparation of transdermal patch as a drug delivery system for treatment of urinary incontinencehttps://www.pharmaradar360.com/article/interference-by-saline-based-reconstitution-of-lyophilized-quality-control-plasm-4b8636f570f38727PharmaRadar360en2026-09-14T00:00:00.000ZInterference by saline-based reconstitution of lyophilized quality control plasma in 75 routine laboratory testshttps://www.pharmaradar360.com/article/efficacy-and-safety-of-celecoxib-combined-with-jintiange-capsules-for-the-treatm-f8b897f6293fe297PharmaRadar360en2026-09-14T00:00:00.000ZEfficacy and Safety of Celecoxib Combined With Jintiange Capsules for the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trialhttps://www.pharmaradar360.com/article/clinical-significance-of-resting-and-dobutamine-stress-myocardial-work-in-cirrho-2c6fc0ec97666692PharmaRadar360en2026-09-14T00:00:00.000ZClinical significance of resting and dobutamine stress myocardial work in cirrhotic cardiomyopathyhttps://www.pharmaradar360.com/article/improving-therapist-adoption-of-evidence-based-practices-with-the-loci-strategy-49a6ac97edcbf0dfPharmaRadar360en2026-09-14T00:00:00.000ZImproving therapist adoption of evidence-based practices with the LOCI strategy: a randomized controlled trialhttps://www.pharmaradar360.com/article/analysis-of-the-role-experiences-of-clinical-nurse-educators-in-the-process-of-i-5723d793e7d5ea7cPharmaRadar360en2026-09-14T00:00:00.000ZAnalysis of the role experiences of clinical nurse educators in the process of improving the nursing education systemhttps://www.pharmaradar360.com/article/a-survey-on-the-current-clinical-use-and-perceptions-of-warm-needle-acupuncture-ecb43b6a39884080PharmaRadar360en2026-09-14T00:00:00.000ZA survey on the current clinical use and perceptions of warm needle acupuncture among Korean medicine doctorshttps://www.pharmaradar360.com/article/clinical-efficacy-and-safety-of-curcumin-for-the-prevention-and-treatment-of-rad-3adc6b63e3e0b97bPharmaRadar360en2026-09-14T00:00:00.000ZClinical efficacy and safety of curcumin for the prevention and treatment of radiation injury: a systematic review and meta-analysis of randomized controlled trialshttps://www.pharmaradar360.com/article/non-invasive-biofeedback-assisted-vs-conventional-pelvic-floor-muscle-training-c-c024152c1924ea13PharmaRadar360en2026-09-14T00:00:00.000ZNon-invasive biofeedback-assisted vs. conventional pelvic floor muscle training combined with high-effort resistance training for urinary incontinence after radical prostatectomy: a randomized controlled trialhttps://www.pharmaradar360.com/article/post-implementation-changes-in-the-procurement-volume-and-patterns-of-oral-hypog-12f2a4df784c8026PharmaRadar360en2026-09-14T00:00:00.000ZPost-implementation changes in the procurement volume and patterns of oral hypoglycemic drugs under China’s National Centralized Drug Procurement policy: an interrupted time-series analysis in Shanghaihttps://www.pharmaradar360.com/article/clinical-characteristics-of-infective-endocarditis-in-children-a-single-center-o-155b307787d443f8PharmaRadar360en2026-09-14T00:00:00.000ZClinical characteristics of infective endocarditis in children: a single center of 10-year experience in Beijinghttps://www.pharmaradar360.com/article/potential-clinical-value-of-mir-122-expression-and-genetic-locus-variants-in-ped-2c58e79476f42db4PharmaRadar360en2026-09-14T00:00:00.000ZPotential clinical value of miR-122 expression and genetic locus variants in pediatric congenital heart diseasehttps://www.pharmaradar360.com/article/a-prognostic-model-integrating-systemic-inflammation-and-clinical-features-for-o-4ba9b87bf15bafe3PharmaRadar360en2026-09-14T00:00:00.000ZA prognostic model integrating systemic inflammation and clinical features for overall survival in lung cancer: development, internal validation, and external evaluationhttps://www.pharmaradar360.com/article/preventability-of-adverse-drug-reactions-to-anticancer-drugs-insights-from-the-d-6e0304153ab4cab5PharmaRadar360en2026-09-14T00:00:00.000ZPreventability of adverse drug reactions to anticancer drugs: insights from the database of the Regional Drug Information and Pharmacovigilance Centerhttps://www.pharmaradar360.com/article/association-of-intraoperative-systolic-blood-pressure-variability-and-clinical-o-ba5dfdd788dcf654PharmaRadar360en2026-09-14T00:00:00.000ZAssociation of intraoperative systolic blood pressure variability and clinical outcomes in mechanical thrombectomy: a retrospective cohort studyhttps://www.pharmaradar360.com/article/advances-in-drug-delivery-systems-for-osteoarthritis-therapy-exosomes-microparti-e0b306b586959ea6PharmaRadar360en2026-09-14T00:00:00.000ZAdvances in drug delivery systems for osteoarthritis therapy: exosomes, microparticles, nanoparticles, and hydrogelshttps://www.pharmaradar360.com/article/paired-oral-clinical-specimens-reveal-the-underlying-ecology-supporting-the-emer-452251b0fbaa9af4PharmaRadar360en2026-09-14T00:00:00.000ZPaired oral clinical specimens reveal the underlying ecology supporting the emergence of inflammophilic microbiome communitieshttps://www.pharmaradar360.com/article/library-strategies-differentially-shape-microbial-functional-and-host-signals-in-ed7d88ee8c97421bPharmaRadar360en2026-09-14T00:00:00.000ZLibrary strategies differentially shape microbial, functional, and host signals in clinical metagenomic sequencinghttps://www.pharmaradar360.com/article/palmar-plantar-ligament-injuries-in-five-horses-clinical-findings-comparative-di-5236f722da22c599PharmaRadar360en2026-09-14T00:00:00.000ZPalmar/plantar ligament injuries in five horses: Clinical findings, comparative diagnostic imaging, therapy and outcomehttps://www.pharmaradar360.com/article/pseudoangiomatous-stromal-hyperplasia-of-the-breast-clinical-radiologic-and-hist-ab64f7b05784a45fPharmaRadar360en2026-09-14T00:00:00.000ZPseudoangiomatous Stromal Hyperplasia of the Breast: Clinical, Radiologic and Histopathologic Spectrum in a Retrospective Single‐Centre Serieshttps://www.pharmaradar360.com/article/assessment-of-pharmacy-professionals-workplace-satisfaction-in-a-conflict-affect-b9bccd32f45054acPharmaRadar360en2026-09-14T00:00:00.000ZAssessment of pharmacy professionals’ workplace satisfaction in a conflict-affected health system: evidence from Yemenhttps://www.pharmaradar360.com/article/the-future-of-pharmaceuticals-strategic-foresight-in-an-era-of-uncertainty-aa902f719a466343PharmaRadar360en2026-09-14T00:00:00.000ZThe future of pharmaceuticals: strategic foresight in an era of uncertaintyhttps://www.pharmaradar360.com/article/clinical-progress-in-gene-therapy-for-rpgr-associated-x-linked-retinitis-pigment-54539ea3fc0cc69fPharmaRadar360en2026-09-14T00:00:00.000ZClinical progress in gene therapy for RPGR-associated X-linked retinitis pigmentosahttps://www.pharmaradar360.com/article/hydrogen-bonded-poly-vinyl-alcohol-tannic-acid-quercetin-hydrogels-for-localized-ac652fd7b3c4269dPharmaRadar360en2026-09-14T00:00:00.000ZHydrogen-Bonded Poly(vinyl Alcohol)/Tannic Acid/Quercetin Hydrogels for Localized Controlled Drug Deliveryhttps://www.pharmaradar360.com/article/i-in-vitro-i-assessments-for-pharmacokinetic-drug-drug-interaction-potential-of-cf08e40435812d90PharmaRadar360en2026-09-14T00:00:00.000Z<i>In vitro</i> assessments for pharmacokinetic drug-drug interaction potential of vornorexant, a novel dual orexin 1/2 receptor antagonisthttps://www.pharmaradar360.com/article/hydrogen-rich-water-ingestion-alleviates-downhill-running-induced-muscle-sorenes-d0207f0a4e64aea6PharmaRadar360en2026-09-14T00:00:00.000ZHydrogen-Rich Water Ingestion Alleviates Downhill Running-Induced Muscle Soreness in Recreationally Active Young Men: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nat10-as-a-context-dependent-epitranscriptomic-hub-governing-cancer-drug-resista-22f80dfb63466a0bPharmaRadar360en2026-09-14T00:00:00.000ZNAT10 as a context-dependent epitranscriptomic hub governing cancer drug resistancehttps://www.pharmaradar360.com/article/impact-of-vascular-and-cardiac-parameters-on-quality-of-life-in-patients-undergo-a52b60a8304f8b42PharmaRadar360en2026-09-14T00:00:00.000ZImpact of vascular and cardiac parameters on quality of life in patients undergoing catheter ablation for atrial fibrillationhttps://www.pharmaradar360.com/article/old-drug-with-new-application-spironolactone-suppresses-panx-1-mediated-ca2-infl-01c4d8120aeb176cPharmaRadar360en2026-09-14T00:00:00.000ZOld drug with new application: spironolactone suppresses Panx 1-mediated Ca2+ influx to attenuate inflammation-driven neutral lipid accumulation in early atherosclerosishttps://www.pharmaradar360.com/article/craniofacial-morphology-and-dental-age-assessment-in-pediatric-craniosynostosis-4c9a55058c7e2458PharmaRadar360en2026-09-14T00:00:00.000ZCraniofacial Morphology and Dental Age Assessment in Pediatric Craniosynostosis: A Comparative Cross‐Sectional Studyhttps://www.pharmaradar360.com/article/environmental-burdens-of-long-term-cadaver-pool-storage-solutions-a-screening-cr-4d8320b83900e71ePharmaRadar360en2026-09-14T00:00:00.000ZEnvironmental Burdens of Long‐Term Cadaver Pool Storage Solutions: A Screening Cradle‐to‐Gate Life Cycle Assessment of Three Formulationshttps://www.pharmaradar360.com/article/practical-computational-exploration-of-chemical-reaction-space-assessing-the-che-e45d4b674d9e7dbfPharmaRadar360en2026-09-14T00:00:00.000ZPractical Computational Exploration of Chemical Reaction Space: Assessing the Chemical Stability of Active Pharmaceutical Ingredients Under Acidic Conditionshttps://www.pharmaradar360.com/article/neonatal-ventilation-training-using-a-low-cost-high-fidelity-simulator-in-a-low-352ce6c5484f86fePharmaRadar360en2026-09-14T00:00:00.000ZNeonatal Ventilation Training Using a Low-Cost, High-Fidelity Simulator in a Low-Resource Settinghttps://www.pharmaradar360.com/article/nct07819110-radicle-healthtm-vip-a-study-assessing-the-impact-of-health-and-well-306e35e216d7a229PharmaRadar360en2026-09-14T00:00:00.000ZNCT07819110: Radicle HealthTM VIP: A Study Assessing the Impact of Health and Wellness Products on Metabolic Health and Related Health Outcomeshttps://www.pharmaradar360.com/article/nct07818590-the-effect-of-nanoparticle-coating-of-orthodontic-brackets-on-the-ra-45cd5b663cc584f2PharmaRadar360en2026-09-14T00:00:00.000ZNCT07818590: The Effect of Nanoparticle Coating of Orthodontic Brackets on The Rate of Canine Retraction: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07818395-spatial-multi-omics-of-perineural-invasion-microenvironment-and-prog-9eae5da708518537PharmaRadar360en2026-09-14T00:00:00.000ZNCT07818395: Spatial Multi-Omics of Perineural Invasion Microenvironment and Prognosis in Prostate Cancerhttps://www.pharmaradar360.com/article/nct07818174-graded-motor-imagery-effects-on-body-perception-disturbance-in-compl-6fa37c136a3eadb5PharmaRadar360en2026-09-14T00:00:00.000ZNCT07818174: Graded Motor Imagery Effects on Body Perception Disturbance in Complex Regional Pain Syndrome : a Randomised Controlled Trialhttps://www.pharmaradar360.com/article/nct07817186-clinical-trial-of-a-mek-inhibitor-for-rasopathy-associated-severe-in-cfc658dba67c417cPharmaRadar360en2026-09-14T00:00:00.000ZNCT07817186: Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIThttps://www.pharmaradar360.com/article/nct07817004-qlm2010-comparative-pharmacokinetic-study-with-2-minute-intravenous-90a7bd456c2fdff5PharmaRadar360en2026-09-14T00:00:00.000ZNCT07817004: QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administrationhttps://www.pharmaradar360.com/article/nct07816731-effect-of-face-to-face-and-virtual-reality-based-salutogenesis-nursi-b72760fa4d356199PharmaRadar360en2026-09-14T00:00:00.000ZNCT07816731: EFFECT OF FACE-TO-FACE AND VIRTUAL REALITY-BASED SALUTOGENESIS NURSING CARE IN PATIENTS WITH DEMENTIAhttps://www.pharmaradar360.com/article/nct07816666-torvutatug-samrotecan-with-or-without-bevacizumab-as-maintenance-tre-ef10e449d172cc7fPharmaRadar360en2026-09-14T00:00:00.000ZNCT07816666: Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancerhttps://www.pharmaradar360.com/article/nct07815678-first-in-human-study-of-the-safety-tolerability-pharmacokinetics-and-7bfba9cc2885eb22PharmaRadar360en2026-09-14T00:00:00.000ZNCT07815678: First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671https://www.pharmaradar360.com/article/nct07810478-criteria-based-rehabilitation-after-tibial-fracture-fixation-a-rando-a829f93786110c1bPharmaRadar360en2026-09-14T00:00:00.000ZNCT07810478: Criteria-Based Rehabilitation After Tibial Fracture Fixation: A Randomized Controlled Trialhttps://www.pharmaradar360.com/article/nct07739459-study-of-zanubrutinib-in-older-patients-with-previously-untreated-ch-8e97594244b216f5PharmaRadar360en2026-09-14T00:00:00.000ZNCT07739459: Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)https://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00PharmaRadar360en2026-09-14T00:00:00.000ZNCT07686380: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapyhttps://www.pharmaradar360.com/article/nct07673913-relationship-of-peripheral-inflammatory-and-neuroprotective-biomarke-2ca4185331048bcbPharmaRadar360en2026-09-14T00:00:00.000ZNCT07673913: Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depressionhttps://www.pharmaradar360.com/article/nct07554339-a-clinical-trial-of-calderasib-mk-1084-and-durvalumab-in-people-with-8682652bb67ca21fPharmaRadar360en2026-09-14T00:00:00.000ZNCT07554339: A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)https://www.pharmaradar360.com/article/nct07516184-explore-the-diagnostic-value-of-bronchodilation-test-with-portable-o-5c13347c1faf4c64PharmaRadar360en2026-09-14T00:00:00.000ZNCT07516184: Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosishttps://www.pharmaradar360.com/article/nct07513389-omission-of-postoperative-radiation-in-hpv-associated-oropharyngeal-54433fa6534bad2bPharmaRadar360en2026-09-14T00:00:00.000ZNCT07513389: Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)https://www.pharmaradar360.com/article/nct07465757-a-study-of-alisertib-and-paclitaxel-in-patients-with-small-cell-lung-dde461375ff0295bPharmaRadar360en2026-09-14T00:00:00.000ZNCT07465757: A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)https://www.pharmaradar360.com/article/nct07451899-tb-type-and-spirometry-result-vs-functional-capacity-based-on-6mwt-i-21d29ab24081d675PharmaRadar360en2026-09-14T00:00:00.000ZNCT07451899: TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Diseasehttps://www.pharmaradar360.com/article/nct07218146-a-study-of-zl-1310-versus-investigator-s-choice-of-therapy-in-partic-767ee1cfeea38d53PharmaRadar360en2026-09-14T00:00:00.000ZNCT07218146: A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)https://www.pharmaradar360.com/article/nct07111065-fast-for-dm-fatty-acid-supplementation-trial-fast-for-dermatomyositi-ed2b3f59cab40468PharmaRadar360en2026-09-14T00:00:00.000ZNCT07111065: FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)